-$0.41 EPS Expected for Stemline Therapeutics Inc (NASDAQ:STML) This Quarter

Equities research analysts forecast that Stemline Therapeutics Inc (NASDAQ:STML) will announce ($0.41) earnings per share for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Stemline Therapeutics’ earnings. The lowest EPS estimate is ($0.53) and the highest is ($0.31). Stemline Therapeutics reported earnings of ($0.73) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 43.8%. The company is expected to report its next quarterly earnings report on Thursday, November 14th.

According to Zacks, analysts expect that Stemline Therapeutics will report full year earnings of ($1.99) per share for the current financial year, with EPS estimates ranging from ($2.32) to ($1.71). For the next year, analysts expect that the firm will report earnings of ($0.11) per share, with EPS estimates ranging from ($1.22) to $1.68. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Stemline Therapeutics.

Stemline Therapeutics (NASDAQ:STML) last issued its earnings results on Friday, August 2nd. The biopharmaceutical company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.05. The company had revenue of $13.01 million during the quarter, compared to the consensus estimate of $8.84 million.

Several research analysts have commented on STML shares. ValuEngine upgraded Stemline Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, August 6th. Zacks Investment Research cut Stemline Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, August 7th. BidaskClub cut Stemline Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 4th. HC Wainwright set a $35.00 price target on Stemline Therapeutics and gave the company a “buy” rating in a report on Thursday, June 20th. Finally, Wedbush raised Stemline Therapeutics from a “neutral” rating to an “outperform” rating in a report on Friday, August 2nd. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $23.50.

In related news, CEO Ivan Bergstein sold 10,822 shares of the firm’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $15.49, for a total transaction of $167,632.78. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Kenneth Hoberman sold 25,817 shares of the firm’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $14.27, for a total value of $368,408.59. The disclosure for this sale can be found here. In the last ninety days, insiders sold 149,177 shares of company stock worth $2,236,377. Insiders own 13.10% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Legal & General Group Plc raised its holdings in shares of Stemline Therapeutics by 27.1% during the 4th quarter. Legal & General Group Plc now owns 5,249 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 1,120 shares in the last quarter. Allianz Asset Management GmbH raised its holdings in shares of Stemline Therapeutics by 7.2% during the 2nd quarter. Allianz Asset Management GmbH now owns 21,309 shares of the biopharmaceutical company’s stock valued at $326,000 after buying an additional 1,427 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Stemline Therapeutics by 18.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 11,004 shares of the biopharmaceutical company’s stock valued at $166,000 after buying an additional 1,715 shares in the last quarter. Knott David M raised its holdings in shares of Stemline Therapeutics by 1.3% during the 1st quarter. Knott David M now owns 157,795 shares of the biopharmaceutical company’s stock valued at $2,028,000 after buying an additional 2,000 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Stemline Therapeutics during the 1st quarter valued at about $36,000. 78.78% of the stock is currently owned by institutional investors.

NASDAQ STML traded up $0.26 during trading hours on Monday, hitting $15.55. The company had a trading volume of 626,600 shares, compared to its average volume of 602,276. Stemline Therapeutics has a 52 week low of $7.82 and a 52 week high of $18.22. The company’s 50 day moving average is $14.29. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.71 and a quick ratio of 5.03. The company has a market capitalization of $725.27 million, a price-to-earnings ratio of -5.20 and a beta of 1.29.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.

Read More: Cash Asset Ratio

Get a free copy of the Zacks research report on Stemline Therapeutics (STML)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.